Literature DB >> 184364

Renal cyclic adenosine monophosphate: an accurate index of parathyroid function.

M K Drezner, F A Neelon, H B Curtis, H E Lebovitz.   

Abstract

Measurement of total urine cyclic 3':5'-adenosine monophosphate (cyclic AMP) only incompletely discriminates between normal, hyperparathyroid, and nonparathyroid hypercalcemic patients. Only a fraction of total urine cyclic AMP is contributed by parathyroid hormone (PTH) action on the proximal nephron (renal cyclic AMP); the remainder is derived from plasma by glomerular filtration. We dtermined total urine and plasma cyclic AMP and PTH (by carboxy-terminal specific radioimmunoassay) in control, hyperparathyroid, nonparathyroid hypercalcemic, and surgically hypoparathyroid patients. Renal cyclic AMP was calculated as total urine cyclic AMP minus the filtered component. Of these determinations, only renal cyclic AMP segregated normal from hyperparathyroid, and hyperparathyroid from nonparathyroid hypercalcemic patients with complete accuracy. These data suggest that measurement of renal cyclic AMP provides an accurate index of parathyroid activity and allows clinical discrimination and appropriate treatment of the sub-groups of patients with malignancy and nonparathyroid hypercalcemia from those with hyperparathyroidism.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 184364     DOI: 10.1016/0026-0495(76)90018-4

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  8 in total

1.  cAMP content in rat urine following 10 and 20 days oral administration of a calcium-binding ion exchanger.

Authors:  R Markstein; V Hagmaier; M Häberle; B Kremer; G Rutishauser
Journal:  Urol Res       Date:  1979-12

2.  Effects of the intravenous administration of magnesium sulfate on corrected serum calcium level and nephrogenous cyclic AMP excretion in normal human subjects.

Authors:  K Suzuki; K Nonaka; N Kono; K Ichihara; Y Fukumoto; Y Inui; J Miyagawa; T Onishi; C Hayashi; S Tarui
Journal:  Calcif Tissue Int       Date:  1986-11       Impact factor: 4.333

3.  [Evaluation of renal cyclic adenosine monophosphate, serum parathyroid hormone and phosphate reabsorption in recurrent calcium urolithiasis, healthy controls and hyperparathyroidism (author's transl)].

Authors:  P O Schwille; C Bornhof; R Thun; D Scholz; R Bötticher; W Schellerer; A Sigel
Journal:  Klin Wochenschr       Date:  1978-06-15

4.  Urinary excretion of cyclic adenosine 3',5'-monophosphate and cyclic guanosine 3',5'-monophosphate in malignancy.

Authors:  C Gennari; G Francini; M Galli; F Lore
Journal:  J Clin Pathol       Date:  1978-08       Impact factor: 3.411

5.  Serum gastrin, calcitonin, and prolactin as markers of multiple endocrine neoplasia syndromes in patients with primary hyperparathyroidism.

Authors:  J R Farndon; J M Geraghty; W G Dilley; S Handwerger; G S Leight
Journal:  World J Surg       Date:  1987-04       Impact factor: 3.352

6.  Nephrogenous cyclic adenosine monophosphate as a parathyroid function test.

Authors:  A E Broadus; J E Mahaffey; F C Bartter; R M Neer
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

7.  Seasonal variation in urinary excretion of cyclic AMP in healthy people.

Authors:  C Gennari; F Loré; M Galli; I D D'Amore; G Francini
Journal:  J Endocrinol Invest       Date:  1981 Jul-Sep       Impact factor: 4.256

8.  The 24-h urinary cyclic adenosine 3', 5' monophosphate/creatinine ratio: an useful approach to the diagnosis of parathyroid disorders and function.

Authors:  A Caniggia; R Nuti; M Galli
Journal:  J Endocrinol Invest       Date:  1981 Jul-Sep       Impact factor: 4.256

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.